Clinical studies of the cefazedone sodium in treatment of respiratory tract bacterial infections
10.3760/cma.j.issn.1673-4904.2010.19.005
- VernacularTitle:头孢西酮钠治疗急性呼吸道细菌感染临床研究
- Author:
Jing YANG
;
Gengzhi GE
;
Hongyuan WANG
- Publication Type:Journal Article
- Keywords:
Randomized controlled trials;
Cefazolin;
Bacterial infections;
Cefazedone
- From:
Chinese Journal of Postgraduates of Medicine
2010;33(19):12-14
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the clinical efficacy and safety of the cefazedone sodium in treatment of respiratory tract bacterial infections. Methods Single-blind randomized control trial was performed to evaluate the efficacy and safety of cefazedone sodium in treatment of respiratory tract bacterial infections, and cefazolin sodium as the controlled one. Patients in trial group (using cefazedone sodium, 35 patients) and control group (using cefazolin sodium, 37 patients) were all intravenously administered at the same doses of 2 g, every 12 hours for 5 to 14 days. A total of 72 patients were enrolled in the studies, 34 in trial group and 32 in control group, with 1 excluded and 5 withdrawn. Safety assessment was conducted in 71 patients. Results In trial group and control group, the total cure rates for respiratory tract infections were 91.18% (31/34) and 78.12%(25/32), and the general bacterial eradication rates were 80.00% (20/25) and 84.00% (21/25). The adverse drug reaction rates were 22.86 %(8/35) and 16.67% (6/36),there was no significant difference (P > 0.05 ). Conclusion Cefazedone sodium is a safe and effective antibiotic in the treatment of acute respiratory tract bacterial infections.
